Image: Pelvital

In an effort to provide women with an innovative and accessible treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles, Pelvital has raised $2.68M in seed funding for its novel product, Flyte. The round was led by Boomerang Ventures. Other participants include VisionTech Partners, Wisconsin Investment Partners, and Edward Bergmark, PhD, the Founder and former CEO of Optum.

Flyte is an FDA-approved, at-home intravaginal device, that delivers mechanotherapy, a proven treatment modality that rapidly and effectively strengthens pelvic floor muscles. Flyte was brought to life through a collaboration between physicians from the Arctic University of Norway and experts in gynecology, muscle rehabilitation, and urinary incontinence treatments. Two clinical trials studied the safety, efficacy, and durability of Flyte in women with SUI. These studies demonstrated that Flyte delivers continence rates and durability comparable to surgery, yet with a conservative, fast, and convenient treatment.

Lydia Zeller, President and CEO of Pelvital, shared: “Pelvital is committed to empowering both women and clinicians with transformative products backed by strong clinical evidence. We are excited to partner with Boomerang as we execute on our vision to be the gold standard of care for treatment of urinary incontinence, an issue that impacts one in two women. Boomerang’s focus on transformative healthcare technology is a perfect match as we introduce our next generation product to the clinical community. In the context of significant gaps in health equity – and in particular for issues that disproportionately impact peri-menopausal and menopausal women – increasing access to clinically proven, patient-centric treatments is vitally important.”

Oscar Moralez, Founder and Managing Partner of Boomerang Ventures, commented: “Boomerang Ventures is driven to solve the biggest challenges in healthcare which is why we’re so excited about this investment in Flyte by Pelvital. Their commitment to innovation, science-backed results, research and development, and user experience is making a significant impact on lives and on the cost of care. We have understood for a long time both the opportunity and the historic underfunding in women’s health care, and we’re beginning to understand how largely neglected the menopause segment is. We are incredibly proud to be part of the contingent addressing this gap.”

The seed funding will be used to complete development of the company’s next generation product and to accelerate commercialization, expanding its reach to a broader audience of clinicians and women seeking an effective, convenient, conservative in-home treatment for stress urinary incontinence.

Show CommentsClose Comments

Leave a comment